MiNA Therapeutics
A platform that enables the development of new medicines that restore normal function to patients’ cells.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 | round | |
£140k | Grant | ||
| Total Funding | 000k | ||
| GBP | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (93 %) | 5 % | 367 % | 839 % | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 26 % | (1931 %) | (3037 %) | (197 %) | 3 % | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
MiNA Therapeutics is a pioneering biotechnology company specializing in small activating RNA (RNAa) therapeutics. These innovative medicines harness the body's innate mechanisms to activate genes, thereby restoring or enhancing normal gene function and protein pathways in cells. MiNA's proprietary pipeline focuses on genetic medicine, aiming to address a broad spectrum of diseases. The company collaborates with leading pharmaceutical firms to expand the application of its technology across various therapeutic areas. MiNA operates in the biotechnology and pharmaceutical markets, targeting both rare and common diseases. Its business model involves developing and advancing RNAa-based therapies through clinical trials, often in partnership with other industry leaders. Revenue is generated through strategic collaborations, research partnerships, and potential future sales of approved therapies.
Keywords: RNAa therapeutics, gene activation, genetic medicine, biotechnology, pharmaceutical, clinical trials, rare diseases, strategic collaborations, protein pathways, innovative medicines.